CNS Pharmacology: General Anesthetics

Introduction / Overview

General anesthetics are indispensable agents in modern medicine, facilitating surgical procedures and invasive diagnostic interventions by inducing reversible loss of consciousness, amnesia, analgesia, muscle relaxation, and autonomic stability. Their clinical utility extends beyond the operating room, encompassing critical care sedation and procedural sedation in outpatient settings. Understanding the pharmacological principles that govern the action of these agents is crucial for safe and effective patient management.

Learning objectives for this chapter are as follows:

• Identify the major classes of general anesthetics and their chemical characteristics.
• Describe the principal mechanisms of action at neuronal and molecular levels.
• Explain the pharmacokinetic properties that influence dosing and clinical outcomes.
• Recognize the approved therapeutic indications and common off‑label uses.
• Recognize key adverse effects, drug interactions, and special population considerations.

Classification

Drug Classes and Categories

General anesthetics can be grouped primarily by route of administration and pharmacodynamic properties:

• Inhalational (volatile) anesthetics – e.g., halothane, isoflurane, sevoflurane, desflurane, xenon. These agents are delivered via gas mixtures and exert effects through gas solubility and membrane partitioning.
• Intravenous (IV) anesthetics – e.g., propofol, etomidate, ketamine, thiopental, barbiturates, and alpha‑2 agonists such as dexmedetomidine. These agents are administered through the bloodstream and act on specific receptor complexes.
• Regional anesthetics – local agents (lidocaine, bupivacaine) used in nerve blocks; although not strictly “general” anesthetics, they are frequently discussed in the context of CNS pharmacology.

Chemical Classification

Inhalational agents are typically halogenated hydrocarbons, characterized by increasing degrees of halogenation and lipophilicity. IV agents encompass diverse chemical families: phenols (propofol), imidazoline derivatives (etomidate), amino‑keto compounds (ketamine), and barbituric acids. Structural features such as aromatic rings, alkyl groups, and heteroatoms influence potency, solubility, and receptor affinity.

Mechanism of Action

Pharmacodynamics of Inhalational Anesthetics

Volatile anesthetics are believed to exert their effects primarily through modulation of neuronal ion channels embedded within lipid bilayers. They increase the permeability of neuronal membranes to chloride ions, thereby hyperpolarizing neuronal membranes and reducing excitability. Key targets include:

• GABA_A receptors – potentiation leads to enhanced inhibitory neurotransmission.
• NMDA receptors – antagonism reduces excitatory glutamatergic activity.
• Two‑pore domain potassium channels (K_2P) – activation contributes to hyperpolarization.

Additionally, anesthetics influence intracellular signaling cascades, including the modulation of MAPK pathways, which may contribute to long‑term neuroplastic changes. The “lipid theory” remains relevant, as the solubility of these agents in membrane phospholipids correlates with anesthetic potency (the Meyer–Overton correlation).

Pharmacodynamics of Intravenous Anesthetics

Intravenous agents act through distinct molecular mechanisms:

• Propofol – enhances GABA_A receptor chloride conductance and inhibits NMDA receptor currents, leading to potent CNS depression.
• Etomidate – selectively potentiates GABA_A receptors, particularly in limbic regions, with minimal cardiovascular depression.
• Ketamine – functions as a dissociative anesthetic by blocking NMDA receptors, thereby reducing excitatory neurotransmission while preserving airway reflexes and sympathetic tone.
• Thiopental and barbiturates – potentiate GABA_A receptor activity and decrease the threshold for action potential generation.
• Dexmedetomidine – activates alpha‑2 adrenergic receptors in locus coeruleus, producing sedation and analgesia without significant respiratory depression.

These pharmacodynamic interactions culminate in a cascade of CNS depression, culminating in the loss of consciousness and analgesia.

Pharmacokinetics

Inhalational Anesthetics

The pharmacokinetic profile of volatile agents is governed by their partition coefficients in blood, lung, and tissue compartments. Key parameters include:

• Blood–gas partition coefficient – determines the rate of equilibration between alveolar gas and arterial blood. Lower coefficients (e.g., desflurane, sevoflurane) facilitate rapid induction and emergence.
• Lipid solubility – influences tissue uptake and redistribution, affecting the depth of anesthesia and recovery time.
• Metabolism – minimal for most agents; however, halothane undergoes hepatic metabolism producing reactive metabolites, whereas isoflurane and sevoflurane are largely exhaled unchanged.

Because inhalational agents are delivered by inhalation, absorption occurs directly through the alveolar membrane, and elimination is primarily via exhalation, resulting in predictable pharmacokinetic behavior. However, changes in ventilation, perfusion, and body temperature can modulate the rate of uptake and elimination.

Intravenous Anesthetics

IV agents exhibit diverse pharmacokinetic characteristics influenced by protein binding, volume of distribution (V_d), hepatic metabolism, and renal excretion:

• Propofol – high lipid solubility, large V_d (~0.7–1.5 L/kg), rapid redistribution to CNS; metabolism via glucuronidation and sulfation; elimination half‑life 1–2 h.
• Etomidate – moderate V_d (~0.6–1.1 L/kg), metabolism by hepatic esterases; elimination half‑life 1–4 h.
• Ketamine – moderate V_d (~1.5–2.5 L/kg), hepatic metabolism to norketamine; elimination half‑life 2–3 h.
• Barbiturates – high V_d, extensive hepatic metabolism; elimination half‑life varies with agent (thiopental ~1–2 h).
• Dexmedetomidine – moderate V_d (~1 L/kg), metabolism by hepatic O‑glucuronidation; elimination half‑life ~2–3 h.

IV agents are administered in precise doses, allowing for rapid titration. However, accumulation can occur in repeated dosing or in patients with hepatic or renal impairment, necessitating dose adjustments.

Therapeutic Uses / Clinical Applications

Approved Indications

General anesthetics are primarily indicated for:

• Induction, maintenance, and emergence from general anesthesia during surgical procedures of varying complexity.
• Sedation in intensive care units for patients requiring mechanical ventilation or invasive monitoring.
• Procedural sedation for interventional radiology, endoscopy, and minor surgical interventions.

Common Off‑Label Uses

Off‑label applications that are frequently encountered include:

• Ketamine for refractory depressive disorders and acute suicidal ideation.
• Propofol infusion syndrome in prolonged sedation protocols.
• Dexmedetomidine for targeted sedation in neurocritical care to preserve neurological assessment.
• Use of inhalational agents as adjuncts in regional blocks to enhance analgesia (e.g., sevoflurane via nebulization).

Adverse Effects

Common Side Effects

Adverse events are influenced by dose, route, and patient factors. Common side effects include:

• Respiratory depression (particularly with IV agents lacking airway reflex suppression).
• Hypotension and vasodilation due to systemic sympathetic inhibition.
• Myocardial depression and arrhythmias, especially with propofol and barbiturates.
• Post‑operative nausea and vomiting (PONV), more prevalent with volatile agents.
• Emergence delirium or hallucinations, particularly with ketamine and high doses of sevoflurane.

Serious or Rare Adverse Reactions

Serious reactions, though infrequent, may include:

• Propofol infusion syndrome – characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure.
• Severe hepatotoxicity with halothane metabolism.
• Severe bronchospasm or anaphylaxis with IV barbiturates or propofol emulsions.
• Reversible cognitive deficits or neurotoxicity with prolonged exposure in vulnerable populations.

Black Box Warnings

Several agents carry black box warnings, including:

• Propofol – due to the risk of propofol infusion syndrome.
• Etomidate – for adrenal suppression with prolonged use.
• Halothane – for hepatotoxicity and malignant hyperthermia susceptibility.

Drug Interactions

Major Drug–Drug Interactions

Interactions can alter pharmacodynamic or pharmacokinetic profiles:

• Propofol – potentiated CNS depression when combined with benzodiazepines, opioids, or alcohol.
• Ketamine – increased seizure threshold when used with antiepileptic drugs; additive sympathomimetic effects with stimulants.
• Etomidate – combined adrenal suppression with other glucocorticoids or adrenal‑suppressing agents.
• Volatile agents – increased risk of malignant hyperthermia in patients with RYR1 mutations or in the presence of succinylcholine or other depolarizing neuromuscular blockers.
• Dexmedetomidine – additive bradycardia and hypotension when combined with beta‑blockers or other sympatholytics.

Contraindications

Absolute or relative contraindications include:

• Known hypersensitivity to the agent or its excipients.
• Severe hepatic dysfunction (e.g., halothane, isoflurane).
• Severe cardiac disease with limited reserve (e.g., high doses of propofol).
• Pregnancy category C or D agents for non‑essential procedures.
• Patients on medications that strongly inhibit or induce CYP450 enzymes, affecting metabolism of IV anesthetics.

Special Considerations

Use in Pregnancy and Lactation

General anesthetics are commonly used during obstetric procedures. Agents with minimal placental transfer (e.g., sevoflurane) are preferred. Ketamine is considered relatively safe due to rapid clearance and low fetal exposure. However, propofol and etomidate may cross the placenta; caution is advised. During lactation, most agents are excreted in breast milk in small amounts, but high doses or prolonged sedation may affect neonatal sleep patterns.

Pediatric and Geriatric Considerations

In children, higher metabolic rates and lower body fat result in faster clearance of volatile agents and shorter duration of action. Dosing must account for age‑related pharmacokinetic changes. Geriatric patients often exhibit reduced hepatic and renal function, altered plasma protein binding, and increased sensitivity to hypotension and respiratory depression. Titration to effect, rather than fixed dosing, is recommended.

Renal and Hepatic Impairment

Renal dysfunction primarily affects agents excreted unchanged, such as the metabolite of etomidate. Hepatic impairment reduces metabolism of propofol, ketamine, and volatile agents, prolonging recovery. Dose adjustments, slower infusion rates, or alternative agents with less hepatic reliance (e.g., sevoflurane) may be necessary.

Summary / Key Points

• General anesthetics are classified into inhalational and intravenous agents, each with distinct chemical structures and pharmacodynamic profiles.
• Volatile anesthetics primarily act by modulating chloride permeability and receptor activity, while IV agents target GABA_A, NMDA, and adrenergic receptors.
• Pharmacokinetics of inhalational agents are dominated by blood–gas partition coefficients, whereas IV agents rely on protein binding, volume of distribution, and metabolic pathways.
• Clinical indications encompass surgical anesthesia, intensive care sedation, and procedural sedation; off‑label uses include psychiatric disorders and neurocritical care.
• Adverse effects range from common respiratory depression to rare, life‑threatening complications such as propofol infusion syndrome or malignant hyperthermia.
• Drug interactions may potentiate CNS depression, alter metabolism, or increase the risk of adverse events; careful medication review is essential.
• Special populations (pregnant, pediatric, geriatric, hepatic or renal impairment) require tailored dosing strategies and vigilant monitoring.
• Understanding the interplay between pharmacodynamics and pharmacokinetics facilitates optimal anesthetic management and enhances patient safety.

References

1. Flood P, Rathmell JP, Urman RD. Stoelting's Pharmacology and Physiology in Anesthetic Practice. 6th ed. Philadelphia: Wolters Kluwer; 2022.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.